Drug intelligence / Profile preview

MAP 315

Development stage: Unknown
Lead developer: Microba Life Sciences
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

MAP 315 is an investigational live biotherapeutic product developed by Microba Life Sciences for the treatment of ulcerative colitis within the broader indication of inflammatory bowel disease. It consists of lyophilised bacteria formulated in an enteric‑coated oral capsule, with the active microorganism being a commensal gut bacterium commonly found in healthy adults. Designed using Microba’s data‑driven microbiome therapeutics platform, MAP 315 aims to beneficially modulate the intestinal microbiota and mucosal immune environment to reduce inflammation and promote intestinal homeostasis in ulcerative colitis. Early clinical development has focused on assessing safety, tolerability, and pharmacokinetics in healthy volunteers through randomized, double‑blind, placebo‑controlled Phase 1 studies.

Beyond the preview

Go deeper on MAP 315.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAP 315.

Explore the full profile